https://www.selleckchem.com/pr....oducts/ag-1024-tyrph
52 months (95% CI 5.9 - 13.1 months). The median overall survival was 12.7 ± 2.2 months (95% CI 8.2 - 17.2). Median time to progression after completion of radiotherapy was 84 days. Grade IV dermatitis and mucositis was encountered in 2.7% and 1.8% cases respectively, requiring hospitalization. Christie regimen for advanced HNSCC is a clinically viable option with acceptable outcomes in a resource constrained setting. Christie regimen for advanced HNSCC is a clinically viable option with acceptable outcomes in a resource cons
Like
Comment
Share
